InspireMD Announces Distribution Agreement for MGuard Prime™ in Chile

InspireMD (NYSE:NSPR) has announced it has signed an agreement with CorpMedical Chile Ltda to distribute the MGuard Prime Embolic Protection System for the treatment of acute coronary syndromes.
As quoted in the press release:

Mr. Jaime Kehr, Chief Executive Officer of CorpMedical Chile Ltda, noted, “MGuard Prime™ with its MicroNet™ technology is a very effective treatment option in STEMI (ST segment elevation in myocardial infarction) patients in the presence of high thrombotic content and in patients with Saphenous Vein Grafts as seen in clinical trials evaluating MGuard. MGuard is the only implant device available in the market we are aware of that offers protection against embolization following stenting in patients with acute myocardial infarction. Given the safety advantages of MGuard™ Prime, supported by positive clinical data demonstrating its ability to significantly reduce the incidence of no-reflow syndrome and its associated risk of increased mortality, we look forward to bringing this technology to market in Chile.”
Agustin Gago, EVP and Chief Commercial Officer of InspireMD, commented, “We are excited to partner with CorpMedical Chile Ltda., which brings long standing relationships with key opinion leaders in Chile. With a population of more than 17 million people, Chile represents an attractive new growth opportunity and will help further expand our presence in Latin America.”

Click here to read the full press release.